"The decision by the European Commission is an important advancement for people living with IgAN in the EU", said Dr. Vinicius Gomes De Lima, Head of Global Medical Affairs at CSL Vifor.

CSL Vifor Logo "Swissmedic approval further demonstrates our promise to deliver transformational medicines for patients with serious diseases in our areas of focus," said Emmanuelle Lecomte Brisset, ...

Australian biopharma CSL has a rich history. The company, which was originally called Commonwealth Serum Laboratories, was started by the government during World War I as a means to get critical ...

CSL Vifor posted a 6% revenue growth, reaching $1.07 billion, slightly exceeding consensus expectations. CSL acquired Vifor Pharma for US$11.7 billion in August 2022, but many analysts believe the ...

CSL investors will get a long-awaited look under the hood at the blood product giant’s strategy for its newly acquired business Vifor on Monday. It will be the first detailed overview of its ...

ST. GALLEN, Switzerland and SAN DIEGO, April 24, 2024 /CNW/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Commission has granted conditional ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...

ST. GALLEN, Switzerland and SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Swissmedic has granted temporary marketing ...

SAN DIEGO & ST. GALLEN, Switzerland--(BUSINESS WIRE)--Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor are pleased to announce that the European Commission has approved the conversion of ...

"Together with our partner, CSL Vifor, we look forward to people living with IgAN in Switzerland gaining access to this important medicine." Swissmedic approval was supported by results from the ...